BIOTRONIK has announced the divestiture of its Vascular Intervention division to Teleflex to refocus on active implantable devices and digital healthcare technologies.
Target Information
BIOTRONIK is a leading global medical technology company, renowned for its innovations in cardiovascular, endovascular, and neuromodulation solutions. Over its 60-year history, the company has focused on engineering precise medical products that significantly enhance patient well-being, particularly for those suffering from heart and blood vessel disorders and chronic pain. Recently, BIOTRONIK has announced a strategic pivot aimed at reinforcing its leadership in active implantable devices and digital healthcare.
The company is leveraging advanced technologies such as artificial intelligence (AI), remote patient monitoring, and connected healthcare platforms to improve patient outcomes and streamline clinical workflows. This strategic refocus allows BIOTRONIK to provide healthcare professionals with cutting-edge tools for personalized and cost-effective treatments.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The medical technology market, particularly in Germany where BIOTRONIK is headquartered, is characterized by an increasing demand for innovative healthcare solutions. With a rapidly aging population and constrained healthca
Similar Deals
Wellhub → Urban Sports Club
2025
Bristol Myers Squibb → Evotec SE
2025
Viessmann Generations Group → schülke
2024
Teleflex Incorporated
invested in
Vascular Intervention division of BIOTRONIK
in 2025
in a Strategic Partnership deal